Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers
Open Access
- 1 January 2024
- journal article
- review article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (2) , 621-642
Abstract
Immune checkpoint inhibitors (ICIs) have generated considerable excitement as a novel class of immunotherapeutic agents due to their remarkable efficacy in treating various types of cancer. However, the widespread use of ICIs has brought about a number of safety concerns, especially the development of immune-related adverse events (irAEs). These serious complications could result in treatment discontinuation and even life-threatening consequences, making it critical to identify high-risk groups and predictive markers of irAEs before initiating therapy. To this end, the current article examines several potential predictive markers of irAEs in important organs affected by ICIs. While retrospective studies have yielded some promising results, limitations such as small sample sizes, variable patient populations, and specific cancer types and ICIs studied make it difficult to generalize the findings. Therefore, prospective cohort studies and real-world investigations are needed to validate the potential of different biomarkers in predicting irAEs risk. Overall, identifying predictive markers of irAEs is a crucial step towards improving patient safety and enhancing the management of irAEs. With ongoing research efforts, it is hoped that more accurate and reliable biomarkers will be identified and incorporated into clinical practice to guide treatment decisions and prevent the development of irAEs in susceptible patients.Keywords
This publication has 209 references indexed in Scilit:
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α productionJournal of Translational Medicine, 2013
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsJournal of Translational Medicine, 2013
- Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosisBritish Journal of Dermatology, 2012
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- A microbial symbiosis factor prevents intestinal inflammatory diseaseNature, 2008
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Acute haemodynamic effects of IL-6 treatment in vivo: Involvement of vagus nerve in NO-mediated negative inotropismCytokine, 2005
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Magnetic Resonance Imaging and Invasive Evaluation of Development of Heart Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-αCirculation, 1999